A series of experimental models were established to investigate the effects of FAP on immune suppression and tumor progression in GBM therapy in vitro and in vivo, and PT100, a small molecule inhibitor of FAP, was also evaluated for the treatment of GBM. Here, FAP is linked to glioblastoma.